Epithelial ovarian cancer: A case report

Area of Science:

• Oncology
• Gynecologic Oncology
• Pharmacology

Background:

• Advanced epithelial ovarian cancer (stage IIIC) presents significant treatment challenges.
• Recurrent or refractory ovarian cancer often requires novel therapeutic approaches.
• This case study examines a patient with late-stage ovarian cancer experiencing disease progression after conventional chemotherapy.

Purpose of the Study:

• To evaluate the efficacy of bevacizumab in managing symptoms of massive ascites and pleural effusion in a patient with recurrent ovarian cancer.
• To assess the role of bevacizumab as a salvage therapy in refractory ovarian cancer.
• To document the patient's response to bevacizumab and subsequent disease course.

Main Methods:

• The patient received conventional chemotherapy with paclitaxel and cisplatin.
• Intraperitoneal carboplatin and bevacizumab were administered for symptom management and disease control.
• Dosage adjustments of bevacizumab were made based on clinical response and tolerance.

Main Results:

• Bevacizumab rapidly resolved massive ascites and pleural effusion, significantly improving the patient's condition.
• The patient achieved disease-free survival for a period after initiating bevacizumab therapy.
• Despite initial response, the patient eventually experienced disease progression and succumbed to multiple organ failure.

Conclusions:

• Bevacizumab demonstrated significant efficacy in rapidly alleviating debilitating symptoms of ascites and pleural effusion in late-stage ovarian cancer.
• The findings suggest bevacizumab is a viable and effective therapeutic option for patients with relapsed and refractory ovarian cancer.
• This case underscores the potential of targeted therapies like bevacizumab in managing complex gynecologic malignancies.